Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
NEW YORK, May 22, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the U.S. District Court for the Southern District of New York on behalf of investors who purchased Neurotrope, Inc. ("Neurotrope") (NASDAQ:NTRP) securities between January 7, 2016, and April 28, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/neurotrope-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the class period, Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” However, the underlying trial data contradicts these representations, as the top-line data relating to the 20 microgram dose of Bryostatin-1 failed to produce results that were statistically significant. In addition, Neurotrope failed to disclose statements regarding the efficacy of the 40 microgram dose with regard to its primary and secondary endpoints. Upon this news, shares of Neurotrope fell from a close of $18.81 on April 28, 2017, to a close of $6.97 per share on May 1, 2017.
If you suffered a loss in Neurotrope you have until July 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/neurotrope-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
